[1] Schmidt MF, Gan ZY, Komander D, Dewson G. Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities. Cell Death & Differentiation. 2021; 28(2):570-90.
[2] Wood BJ, Brackett ED, Hall NM, Cannon CE, Dayton RD, Keller CM, Goeders NE, Murnane KS. 96-h methamphetamine self-administration elicits striatal dopamine depletion in male and female rats: a model of binge-like use. Psychopharmacology. 2025; 24:1-1.
[3] Zhao YL, Zhao W, Liu M, Liu L, Wang Y. Tbhq‐overview of multiple mechanisms against oxidative stress for attenuating methamphetamine‐induced neurotoxicity. Oxidative medicine and cellular longevity. 2020; 2020(1):8874304.
[4] Nie L, Zhao Z, Wen X, Luo W, Ju T, Ren A, Wu B, Li J. Gray-matter structure in long-term abstinent methamphetamine users. BMC psychiatry. 2020; 10: 20(1):158.
[5] Shrestha P, Katila N, Lee S, Seo JH, Jeong JH, Yook S. Methamphetamine induced neurotoxic diseases, molecular mechanism, and current treatment strategies. Biomedicine & Pharmacotherapy. 2022; 1;154:113591.
[6] Paulus MP, Stewart JL. Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA psychiatry. 2020; 1;77(9):959-66.
[7] Kim B, Yun J, Park B. Methamphetamine-induced neuronal damage: neurotoxicity and neuroinflammation. Biomolecules & therapeutics. 2020; 15;28(5):381.
[8] Richards JR, Laurin EG. Methamphetamine toxicity. InStatPearls 2023 Jun 8. StatPearls Publishing.
[9] Wang Y, Zhang X, Liu S, Gu Z, Sun Z, Zang Y, Huang X, Wang Y, Wang Q, Lin Q, Liu R. Bi-directional communication between intrinsic enteric neurons and ILC2s inhibits host defense against helminth infection. Immunity. 2025; 11;58(2):465-80.
[10] Zeng Y, Liu B, Zhou L, Zeng W, Tian X, Jiang J, Dai D. Safety issues of Donepezil combined with Memantine in Alzheimer’s disease population: real-world pharmacovigilance. Expert Opinion on Drug Safety. 2025; 23:1-1.
[11] Yaghmaei E, Lu H, Ehwerhemuepha L, Zheng J, Danioko S, Rezaie A, Sajjadi SA, Rakovski C. Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer’s disease patients. Communications Medicine. 2024; 23;4(1):99.
[12] Pichardo-Rojas D, Pichardo-Rojas PS, Cornejo-Bravo JM, Serrano-Medina A. Memantine as a neuroprotective agent in ischemic stroke: preclinical and clinical analysis. Frontiers in neuroscience. 2023; 19;17:1096372.
[13] Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend. 2020.108177.
[14] Tuo QZ, Zhang ST, Lei P. Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications. Medicinal research reviews. 2022; 42(1):259-305.
[15] Madajewski B, Chen F, Yoo B, Turker MZ, Ma K, Zhang L, et al. Molecular engineering of ultrasmall silica nanoparticle–drug conjugates as lung cancer therapeutics. Clin Cancer Res. 2020; 26(20):5424-37.
[16] Guo Z, Wu L, Wang Y, Zhu Y, Wan G, Li R, et al. Design of dendritic large-pore mesoporous silica nanoparticles with controlled structure and formation mechanism in dual-templating strategy. ACS Appl Mater Interfaces. 2020;12(16):18823-32.
[17] Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend. 2020.108177.
[18] Li X, et al. Functionalized Mesoporous Silica Nanoparticles for Enhanced Drug Delivery and Bioimaging. Adv Funct Mater. 2023;33(15):2210456.
[19] Rahimi-Ghasrodashti M, et al. Development and characterization of silica-based nanocarriers for controlled release of therapeutic agents. J Nanoparticle Res. 2024; 26(3):78.
[20] Zhu J, Zhang Y, Chen X, Zhang Y, Zhang K, Zheng H, Wei Y, Zheng H, Zhu J, Wu F, Piao JG. Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB. Biochemical and Biophysical Research Communications. 2021; 1;534:902-7.
[21] Chen Z, Peng B, Xu JQ, Xiang XC, Ren DF, Yang TQ, Ma SY, Zhang K, Chen QM. A non-surfactant self-templating strategy for mesoporous silica nanospheres: beyond the Stöber method. Nanoscale. 2020;12(6):3657-62.
[22] Wang L, et al. Amelioration of methamphetamine-induced neurotoxicity by antioxidant nanotherapeutics: An in vitro study. Free Radic Biol Med. 2023;199:105-117.
[23] Zhang Y, et al. Advanced silica-based nanocarriers for targeted drug delivery and neuroprotection. Adv Drug Deliv Rev. 2025; 210:115200.
[24] Kim S, et al. ROS scavenging properties of amine-functionalized mesoporous silica nanoparticles for neuroprotection. J Mater Chem B. 2025;13(5):980-992.
[25] Johnson A, et al. Deciphering the molecular mechanisms of neuroprotection by novel drug delivery systems. Cell Death Differ. 2023;30(11):2345-2358.
[26] US20060035889A1, Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists; Loyola University Chicago, Omeros Corp, 2006-02-16.
)